BCL2L13: A Potential Drug Target and Biomarker (G23786)

Target Name: BCL2L13

NCBI ID: G23786

BCL2L13

BCL2L13: A Potential Drug Target and Biomarker

BCL2L13, also known as B2L13_HUMAN, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the BCL2 family of proteins, which are known for their role in regulating cell death and cell proliferation. BCL2L13 has been identified as a potential drug target and is currently being studied as a potential biomarker for a variety of diseases, including cancer.

The BCL2 family of proteins was discovered through the use of genetic screening techniques. The BCL2 gene was identified and the gene was expressed in a variety of tissues, including brain, spinal cord, and peripheral blood. The BCL2 protein was found to be expressed in these tissues and was shown to play a role in the regulation of cell death and cell proliferation.

One of the defining features of the BCL2 protein is its ability to induce cell death in a variety of cell types. This is accomplished through the inhibition of the BCL2 gene, which results in the production of BCL2L13. BCL2L13 has been shown to induce cell death in a variety of cell types, including cancer cells, and may be a useful drug target for cancer treatment.

In addition to its ability to induce cell death, BCL2L13 is also known for its ability to regulate cell proliferation. This is accomplished through the inhibition of the TP53 gene, which is a protein that is responsible for regulating cell growth and division. The inhibition of TP53 gene has been shown to result in the growth arrest and apoptosis of cancer cells.

The potential drug target for BCL2L13 is its ability to induce cell death and its role in the regulation of cell proliferation. This makes it an attractive target for cancer treatment, as cancer cells are known to have increased levels of BCL2L13 and to be less responsive to traditional cancer therapies.

In addition to its potential as a cancer drug, BCL2L13 is also being studied as a potential biomarker for a variety of diseases. The expression of BCL2L13 has been shown to be elevated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This makes BCL2L13 an attractive candidate for use as a diagnostic or therapeutic biomarker.

In conclusion, BCL2L13 is a protein that is expressed in a variety of tissues throughout the body and is known for its ability to induce cell death and regulate cell proliferation. Its potential as a drug target and biomarker make it an attractive candidate for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of BCL2L13 in disease and to develop safe and effective treatments.

Protein Name: BCL2 Like 13

Functions: May promote the activation of caspase-3 and apoptosis

The "BCL2L13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL2L13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets